Nursing Elites

1. A client is starting therapy with doxorubicin. Which of the following findings should the nurse instruct the client to report?

• A. Hair loss
• B. Fatigue
• C. Sore throat
• D. Red urine

Correct answer: C

Rationale: The correct answer is 'C: Sore throat.' Doxorubicin is known to have immunosuppressive effects, which can predispose the client to infections. A sore throat can be an early sign of infection, and prompt reporting to the healthcare provider is crucial to initiate appropriate interventions and prevent complications. Choices A, B, and D are incorrect because hair loss, fatigue, and red urine are common side effects of doxorubicin and are typically expected during therapy. While these side effects should be monitored, they do not require immediate reporting unless they become severe or concerning.

2. When starting therapy with Lisinopril, a client should be instructed to monitor for which of the following adverse effects?

• A. Tinnitus
• B. Diarrhea
• C. Cough
• D. Weight gain

Correct answer: C

Rationale: When starting therapy with Lisinopril, a client should be instructed to monitor for a persistent dry cough as an adverse effect. Lisinopril, an ACE inhibitor, commonly causes this cough as an adverse effect. It is important for the client to monitor for this symptom and notify their healthcare provider if it occurs. Choices A, B, and D are incorrect because tinnitus, diarrhea, and weight gain are not commonly associated adverse effects of Lisinopril.

3. A client is prescribed Amlodipine. Which of the following adverse effects should the nurse monitor?

• A. Tachycardia
• B. Peripheral edema
• C. Hyperglycemia
• D. Hypertension

Correct answer: B

Rationale: Corrected Rationale: Amlodipine, a calcium channel blocker, can lead to peripheral edema as an adverse effect. The nurse should assess the client for swelling in the lower extremities, a common manifestation of this side effect. Monitoring for peripheral edema is crucial to ensure early detection and appropriate management. Tachycardia (Choice A) is not a common adverse effect of Amlodipine. Hyperglycemia (Choice C) is not typically associated with Amlodipine use. Hypertension (Choice D) is the condition for which Amlodipine is prescribed to treat, not an adverse effect of the medication.

4. A healthcare provider is reviewing a client's medical history and notes that the client has a prescription for Digoxin. Which of the following findings is a manifestation of Digoxin toxicity?

• A. Elevated blood pressure
• B. Bradycardia
• C. Yellow-tinged vision
• D. Ringing in the ears

Correct answer: C

Rationale: Yellow-tinged vision, along with nausea, vomiting, and confusion, are common manifestations of Digoxin toxicity. Visual disturbances are important to recognize as they can indicate the need for immediate medical attention and potential adjustment of Digoxin therapy to prevent serious complications. Elevated blood pressure is not typically associated with Digoxin toxicity; instead, hypotension may occur. Bradycardia is a common therapeutic effect of Digoxin rather than a sign of toxicity. Ringing in the ears, or tinnitus, is also a potential side effect of Digoxin but is less specific to toxicity compared to yellow-tinged vision.

5. A client has a new prescription for Enoxaparin. Which of the following instructions should the nurse include?

• A. Massage the injection site after administration.
• B. Aspirate before injecting the medication.
• C. Administer the medication into the abdomen.
• D. Administer the medication via intramuscular injection.

Correct answer: C

Rationale: The correct answer is to administer the medication into the abdomen. Enoxaparin is a medication that is administered subcutaneously, typically in the abdomen to ensure proper absorption. Massaging the injection site should be avoided as it can lead to bruising or bleeding under the skin. Aspirating before injecting the medication is not necessary for subcutaneous injections like Enoxaparin. Administering the medication via intramuscular injection is incorrect as Enoxaparin should be given subcutaneously.

Similar Questions